TELA Bio Receives Nasdaq Delisting Notice for Failing Minimum Bid Price Requirement

summarizeSummary

TELA Bio, Inc. received a Nasdaq deficiency letter for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day period to regain compliance and avoid potential delisting.

check_boxKey Events

• Nasdaq Deficiency Notice Received

  On March 17, 2026, TELA Bio, Inc. received a letter from Nasdaq notifying the company that its common stock's closing bid price has been below the minimum $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).

• 180-Day Compliance Period Granted

  The company has been granted 180 calendar days, until September 14, 2026, to regain compliance. To do so, the bid price of its common stock must close at $1.00 or more for a minimum of 10 consecutive business days.

• Potential for Delisting

  Failure to regain compliance within the initial period may lead to a second 180-day period if the company transfers to The Nasdaq Capital Market. However, there is no assurance that the company will regain compliance or avoid delisting, which could significantly impact its trading status.

auto_awesomeAnalysis

TELA Bio, Inc. has received a deficiency letter from Nasdaq for failing to maintain the minimum $1.00 bid price for continued listing. This is a critical event for the company, as failure to regain compliance could lead to delisting from The Nasdaq Global Market. While there is a 180-day compliance period and a potential for a second period, the company's current stock price of $0.7781 indicates a significant challenge to meet the $1.00 threshold. Delisting could severely impact the company's liquidity and investor confidence, making it harder to raise capital in the future.